Effect of YM158, a Dual Lipid Mediator Antagonist, on Immudiate and Late Asthmatic Responses, and Airway Hyper-responsiveness in Guinea Pigs

DOI Web Site Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 被引用文献3件 参考文献56件
  • Arakida Yasuhito
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Ohga Keiko
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Suwa Kiyomi
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Okada Yohei
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Morio Hiroki
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Yokota Masaki
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Miyata Keiji
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Yamada Toshimitsu
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan
  • Honda Kazuo
    Inflammation Research Pharmacology Laboratories,Institute for Drug Discovery Research,Yamanouchi Pharmaceutical Co.,Ltd.,21 Miyukigaoka,Tsukuba-shi,Ibaraki 305-8585,Japan

書誌事項

タイトル別名
  • Effect of YM158, a Dual Lipid Mediator Antagonist, on Immediate and Late Asthmatic Responses, and on Airway Hyper-responsiveness in Guinea Pigs.

この論文をさがす

抄録

The effects of lipid mediator antagonists:the LTD4-receptor antagonist pranlukast, the TXA2-receptor antagonist seratrodast, and the novel dual LTD4- and TXA2-receptor antagonist YM158(3-[(4-tert-butylthiazol-2-yl)methoxy]-5′-[3-(4-chlorobenzenesulfonyl)propyl]-2′-(1H-tetrazol-5-ylmethoxy)benzanilide monosodium salt monohydrate)were investigated in animals exhibiting immediate asthmatic response(IAR), late asthmatic response(LAR)and airway hyper-responsiveness(AHR).Antigen-induced LAR and AHR are inhibited by orally administered pranlukast(30, 100mg/kg) and seratrodast(3, 10mg/kg).YM158(30mg/kg), orally administered before or after IAR induction, also inhibited both LAR and AHR.However, while the inhibitory effects of pranlukast and seratrodast on IAR were marginal, the effects of YM158(3, 10, 30mg/kg) were dose-dependent, probably due to its multiple sites of action.Additionally, orally administered YM158(30mg/kg) inhibited ozone-induced AHR in guinea pigs.Thus, an antagonist that inhibits several lipid mediators might exhibit greater efficacy in treating asthmatic responses than antagonists with a single site of action.Therefore, YM158 shows great promise as a drug that will be able to treat bronchial asthma and related disorders more potently than currently used single-pathway inhibitors.

収録刊行物

  • Jpn.J.Pharmacol.

    Jpn.J.Pharmacol. 82 (4), 287-294, 2000

    公益社団法人 日本薬理学会

被引用文献 (3)*注記

もっと見る

参考文献 (56)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ